Adjusting the treatment based on the presence of specific molecular alterations has significantly improved the outcome for specific subtypes of AML, such as acute promyelocytic leukemia (APL) and core-binding factor AML (CBF-AML), where the 5-year OS is over 70% with modern protocols6,7. This evidence concerns the gene CEBPZ and acute promyelocytic leukemia.